Tonic Clonic Epilepsy — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for tonic clonic epilepsy. 77 active patents protecting 2 drugs from 2+ originators. First major cliff: 2028. Daily refresh.

2
Approved drugs
77
Active US patents
61/100
Avg vulnerability
—
Annual revenue covered

Originators in Tonic Clonic Epilepsy

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Janssen 70 patents Novartis AG (originally Geigy) 7 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating tonic clonic epilepsy. Each bar = one year. Y-axis scaled to peak year (36 patents).

36
27
6
28
3
29
26
33
6
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Topamax
topiramate
 Janssen 70 66 — 2027-11-16
Tegretol
carbamazepine
 Novartis AG (originally Geigy) 7 55 — 2028-11-10

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8663683 Topamax method of use 80 2027-11-16
8889191 Topamax method of use 80 2027-11-16
8877248 Topamax method of use 80 2027-11-16
8663683 Topamax method of use 80 2027-11-16
8663683 Topamax method of use 80 2027-11-16
8889191 Topamax method of use 80 2027-11-16
8298580 Topamax method of use 80 2027-11-16
8298580 Topamax method of use 80 2027-11-16
8877248 Topamax method of use 80 2027-11-16
8298580 Topamax method of use 80 2027-11-16

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9555005 Topamax formulation 42 2033-03-19
9101545 Topamax formulation 42 2033-03-19
9555005 Topamax formulation 42 2033-03-19
9101545 Topamax formulation 42 2033-03-19
9555005 Topamax formulation 42 2033-03-19
9555005 Topamax formulation 42 2033-03-19
9101545 Topamax formulation 42 2033-03-19
9101545 Topamax formulation 42 2033-03-19
9101545 Topamax formulation 42 2033-03-19
9555005 Topamax formulation 42 2033-03-19

Related